All AbMole products are for research use only, cannot be used for human consumption.
MRX-2843 is a potent and orally active inhibitor of MERTK and FLT3 with IC50 values of 1.3 nM and 0.64 nM, respectively. MRX-2843 induces apoptosis and inhibits colony formation in AML cell lines. In MOLM-14 cells, treatment with MRX-2843 inhibits phosphorylation of FLT3 and downstream signaling through STAT5, ERK1/2 and AKT.
In vivo, MRX-2843 is 78% orally bioavailable at a dose of 3 mg/kg with a Cmax of 1.3 μM and a t1/2 of 4.4 hours. In MOLM-14 parental xenografts, both quizartinib and MRX-2843 increase median survival compare with that of vehicle-treated mice (172.5 days versus 40 days and 121 days versus 36 days, respectively, P<0.001).
Molecular Weight | 488.67 |
Formula | C29H40N6O |
CAS Number | 1429882-07-4 |
Solubility (25°C) | DMSO 50 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Related FLT3 Products |
---|
4SC-203
4SC-203 is a potent multikinase inhibitor with potential antineoplastic activity. |
AKN-028
AKN-028, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6 nM. |
FLT3-IN-3
FLT3-IN-3 is a potent FLT3 inhibitor with IC50s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively. |
MAX-40279
MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. |
FLT3-IN-10
FLT3-IN-10 is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.